TRAVERE THERAPEUTICS, INC. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/f9ee4c2e-e555-47c8-ad96-7d141959de56/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-25.5M | 2025-01-01 – 2025-12-31 | evidence 0001438533-26-000014 |
| FY 2024 | $-321.5M | 2024-01-01 – 2024-12-31 | evidence 0001438533-25-000010 |
| FY 2023 | $-111.4M | 2023-01-01 – 2023-12-31 | evidence 0001438533-24-000005 |
| FY 2022 | $-278.5M | 2022-01-01 – 2022-12-31 | evidence 0001438533-23-000008 |
| FY 2021 | $-180.1M | 2021-01-01 – 2021-12-31 | evidence 0001438533-22-000008 |
| FY 2020 | $-169.4M | 2020-01-01 – 2020-12-31 | evidence 0001438533-21-000008 |
| FY 2019 | $-146.4M | 2019-01-01 – 2019-12-31 | evidence 0001438533-20-000004 |
| FY 2018 | $-102.7M | 2018-01-01 – 2018-12-31 | evidence 0001438533-19-000003 |
| FY 2017 | $-59.7M | 2017-01-01 – 2017-12-31 | evidence 0001438533-18-000006 |
| FY 2016 | $-47.9M | 2016-01-01 – 2016-12-31 | evidence 0001438533-17-000005 |
| FY 2015 | $117.2M | 2015-01-01 – 2015-12-31 | evidence 0001628280-16-011857 |
| FY 2014 | $-110.9M | 2014-01-01 – 2014-12-31 | evidence 0001628280-16-011857 |
| FY 2013 | $-34.6M | 2013-01-01 – 2013-12-31 | evidence 0001628280-16-011857 |
| FY 2012 | $-38.4M | 2011-03-11 – 2013-03-31 | evidence 0001193805-13-001332 |
| FY 2011 | $-14.8k | 2011-03-02 – 2012-02-29 | evidence 0001225279-12-000073 |
| FY 2010 | $-23.0k | 2010-03-01 – 2011-02-28 | evidence 0001225279-12-000073 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TRAVERE THERAPEUTICS, INC. — all facts · Revenue · Operating Income